Are there Food and Drug Administration (FDA)‑approved appetite‑suppressing medications for obesity management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, there are multiple FDA-approved appetite-suppressing medications for obesity management.

The most effective appetite-suppressing medications currently available are the GLP-1 receptor agonists (semaglutide and liraglutide) and the dual GLP-1/GIP agonist tirzepatide, which work by suppressing appetite, increasing satiety, and delaying gastric emptying. 1

Current FDA-Approved Appetite-Suppressing Medications

First-Line: GLP-1 and Dual Agonists (Strongest Evidence)

  • Semaglutide 2.4 mg (Wegovy) - FDA approved 2021

    • Achieves 14.9-16.0% total body weight loss at 68 weeks 1
    • Dosed subcutaneously once weekly
    • Reduces cardiovascular events (HR 0.80; 95% CI 0.72-0.90) in patients with CVD 1
    • Start 0.25 mg weekly, titrate gradually to minimize nausea/vomiting
    • The 2022 AGA guideline suggests prioritizing semaglutide over other agents given its magnitude of benefit 2

  • Tirzepatide (Zepbound) - FDA approved November 2023

    • Achieves 15.0-20.9% weight loss at 72 weeks (dose-dependent: 5-15 mg) 1
    • Superior to semaglutide by 5.1% additional weight loss 1
    • Dosed subcutaneously once weekly
    • Dual mechanism: GLP-1 + GIP receptor agonist

  • Liraglutide 3.0 mg (Saxenda) - FDA approved 2014

    • Achieves 8.0% weight loss at 56 weeks 1
    • Dosed subcutaneously daily
    • Less effective than semaglutide but more affordable and widely available 1
    • Start 0.6 mg daily, increase by 0.6 mg weekly to 3.0 mg 3
    • Discontinue if <4% weight loss at 16 weeks 3

Alternative Oral Appetite Suppressants

  • Phentermine/Topiramate ER (Qsymia) - FDA approved 2012

    • Achieves 5.1-10.9% weight loss at 56 weeks (dose-dependent) 1
    • Mechanism: Norepinephrine release (appetite suppression) + GABA modulation (decreased caloric intake) 3
    • Start 3.75/23 mg daily for 14 days, then 7.5/46 mg
    • Discontinue if <3% loss at 12 weeks on 7.5/46 mg or <5% loss at 12 weeks on 15/92 mg 3
    • Useful for patients with comorbid migraines 1

  • Naltrexone/Bupropion SR (Contrave) - FDA approved 2014

    • Achieves ~6% weight loss at 56 weeks 1
    • Mechanism: Activates POMC neurons, releases α-MSH (appetite suppression) 3
    • Titrate from 1 tablet daily to 2 tablets twice daily (32/360 mg total) 3
    • Consider for patients with comorbid depression or smoking cessation needs 1

  • Phentermine (monotherapy) - FDA approved for short-term use (3 months)

    • Adrenergic agonist: increases norepinephrine, suppresses appetite 3
    • Dose: 15-37.5 mg daily (individualize to lowest effective dose) 3
    • Many providers prescribe off-label for longer durations 3

  • Lorcaserin (Belviq) - WITHDRAWN February 2020 due to cancer risk 4

    • Do not prescribe

Non-Appetite Mechanism (For Comparison)

  • Orlistat (Xenical/Alli) - FDA approved 1999
    • Achieves only 2.9-4.8% weight loss 1
    • Mechanism: Blocks fat absorption (not appetite suppression) 3
    • Recent AGA guidelines conditionally recommend against orlistat due to modest efficacy and GI side effects 1
    • Consider only when other medications contraindicated/unavailable 1

Clinical Implementation Algorithm

Step 1: Determine Eligibility

  • BMI ≥30 kg/m² OR BMI ≥27 kg/m² with weight-related complications
  • Inadequate response to lifestyle interventions 2

Step 2: Select Medication Based on Clinical Profile

Clinical Scenario Preferred Agent Rationale
Most patients seeking maximum weight loss Tirzepatide or Semaglutide Greatest efficacy (15-21% loss) [1]
Patients with CVD or high CV risk Semaglutide Proven CV benefit [1]
Patients with diabetes GLP-1 agonists Dual glycemic + weight benefit [3,1]
Patients with migraines Phentermine/Topiramate Topiramate prevents migraines [1]
Patients with depression/smoking Naltrexone/Bupropion Dual psychiatric benefit [1]
Cost/access barriers Liraglutide or Phentermine More affordable options [1]

Step 3: Titrate and Monitor

  • Gradual dose escalation minimizes GI side effects (nausea, vomiting)
  • Discontinue if inadequate response at specified timepoints (see above)
  • Medications must be used chronically - weight regain occurs upon cessation 1

Critical Safety Considerations

GLP-1/GIP Agonists:

  • Contraindicated: Personal/family history of medullary thyroid carcinoma or MEN2 3
  • Monitor for: Pancreatitis, gallbladder disease, gastroparesis 2
  • Pregnancy: Contraindicated (teratogenic) 3

Phentermine-containing products:

  • Contraindicated: Uncontrolled hypertension, hyperthyroidism, glaucoma, MAOIs (within 14 days), history of drug abuse 3

Naltrexone/Bupropion:

  • Contraindicated: Seizure disorders, eating disorders, uncontrolled hypertension, opioid use 3

Common Pitfalls to Avoid

  1. Discontinuing effective medications prematurely - Weight regain is rapid and substantial (6.9-11.6% regain within 48-52 weeks) 1. These are chronic medications.

  2. Requiring lifestyle intervention "failure" before pharmacotherapy - The 2022 AGA guideline found insufficient evidence to delay medications; integrate CLI and pharmacotherapy simultaneously 2

  3. Using orlistat as first-line - Modest efficacy (2.9%) and poor tolerability make it a last-resort option 1

  4. Ignoring cardiovascular benefits - Semaglutide reduces major adverse cardiovascular events beyond weight loss alone 1

  5. Inadequate dose titration - Slow titration of GLP-1 agonists reduces nausea/vomiting and improves adherence 3

Emerging Therapies (Not Yet FDA-Approved for Obesity)

  • Oral semaglutide (50 mg): 15.1% weight loss in trials, not yet approved 1
  • Retatrutide (triple agonist): In clinical trials 5, 6
  • Orforglipron (oral GLP-1): In development 5, 6

References

Related Questions

What are the recommended pharmacologic agents for obesity management, including indications, dosing, contraindications, and monitoring parameters?
What stimulant is most appropriate for weight loss in a 35-year-old adult with obesity?
In an obese patient with a cervical collar undergoing cervical spine surgery, which site is preferred for central venous catheter placement?
What FDA‑approved pharmacologic agents are available for chronic obesity management, including their dosing regimens and associated side effects?
Which laboratory tests should be ordered for a 7-year-old child with obesity?
Why are sinus infections less common in children compared to older children and adults?
What is the most effective nasal protectant to prevent dryness caused by CPAP nasal pillows?
Does Flonase (fluticasone propionate) contain steroids?
What blood pressure target should be aimed for in an elderly female patient in her late 80s or older who has sinus bradycardia?
For a scalp cyst, is a clinical evaluation together with history and high‑resolution ultrasound sufficient before surgical excision, or are additional investigations always required, and what surgical precautions should be taken to prevent delayed wound healing?
Which otic drops are safe to use in a perforated tympanic membrane?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.